TNFSF11 and breast cancer: In line with the UKCTOCS study, levels of RANKL declined with the manifestation of breast cancer (p = 0.006; paired t-test), whereas RANKL serum concentrations were not altered in subjects with other types of new-onset cancer and those remaining free of neoplastic disease (Figure 4A).